Kevin P. Baker

Kevin Baker joined Pionyr in 2018. He leads research, nonclinical development, and project management. Dr. Baker has over 30 years of research and development experience, including more than 25 years in the biopharmaceutical industry. Prior to joining Pionyr, he was Senior Vice President of Development Sciences at Five Prime Therapeutics, where he oversaw the nonclinical development and manufacturing for all of FivePrime’s clinical programs. Prior to FivePrime, Dr. Baker was Associate Director at Human Genome Sciences (HGS) where he ran a research team focused on receptor-ligand interactions in the immune system, as well as the project team lead for Belimumab, a monoclonal antibody directed against BLyS BAFF Belimumab is currently marketed for the treatment of SLE (lupus).

Prior to Human Genome Sciences, Dr. Baker was a scientist leading a research lab in the molecular biology group at Genentech and was responsible for identifying, cloning and functional analysis of novel secreted proteins including receptor tyrosine kinases and DNases. Dr. Baker holds a Ph.D. in microbial genetics and molecular biology from the University of Dundee, Scotland, and performed postdoctoral studies in cell biology at the Biozentrum in the University of Basel, Switzerland.